Insight Molecular Diagnostics
IMDX
42 hedge funds and large institutions have $7.7M invested in Insight Molecular Diagnostics in 2016 Q1 according to their latest regulatory filings, with 42 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.33% more ownership
Funds ownership: 0% → 0.33% (+0.33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$4.84M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$421K |
| 3 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$412K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$322K |
| 5 |
AG
Artal Group
Luxembourg
|
+$284K |
Top Sellers
IMDX Hedge Fund Activity: Q1 2016 in Review
42 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q1 2016, worth a combined $7.7M.
Buyers outnumbered sellers: 42 funds opened new IMDX positions and 0 closed out — a net gain of 42 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Broadwood Capital, opening a new position worth an estimated $4.84M.
- 42 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q1 2016, up from 0 in Q4 2015.
- Funds reported $7.7M of Insight Molecular Diagnostics stock for Q1 2016.
- 42 funds opened new Insight Molecular Diagnostics positions in Q1 2016 and 0 closed out, a net change of +42 holders.
- The largest Insight Molecular Diagnostics buyer in Q1 2016 was Broadwood Capital, an estimated $4.84M added.
Based on aggregated 13F filings for Q1 2016.